Contraception and the Risk of Type 2 Diabetes Mellitus in Latina Women With Prior Gestational Diabetes Mellitus | Pregnancy | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.100.128. Please contact the publisher to request reinstatement.
1.
Spellacy WN, Buhi WC, Birk SA.  et al.  Carbohydrate metabolism studies in women using Brevicon, a low estrogen oral contraceptive for one year.  J Reprod Med.1982;142:105-108.Google Scholar
2.
Spellacy WN, Bird SA, Buggie J.  et al.  Prospective carbohydrate metabolism studies in women using a low estrogen oral contraceptive for one year.  J Reprod Med.1981;26:295-298.Google Scholar
3.
Luyckx AS, Gaspard UJ, Romus MA.  et al.  Carbohydrate metabolism in women who used oral contraceptives containing levonorgestrel or desogestrel: a 6-month prospective study.  Fertil Steril.1986;45:635-642.Google Scholar
4.
Vermeulen A, Thiery M. Metabolic effects of the triphasic oral contraceptive Trigynon.  Contraception.1982;26:505-513.Google Scholar
5.
van der Vange N, Kloosterboer HJ, Haspels AA. Effect of seven low-dose combined oral contraceptive preparations on carbohydrate metabolism.  Am J Obstet Gynecol.1987;156:918-922.Google Scholar
6.
Rimm EB, Manson JE, Stampfer MJ.  et al.  Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women.  Diabetologia.1992;35:967-972.Google Scholar
7.
Metzger BE, Cho NH, Roston SM, Rodvany R. Prepregnancy weight and antepartum insulin secretion predict glucose tolerance five years after gestational diabetes.  Diabetes Care.1993;16:1598-1605.Google Scholar
8.
Kjos SL, Peters RK, Xiang A, Henry OA, Montoro M, Buchanan TA. Predicting future diabetes in Latino women with gestational diabetes.  Diabetes.1995;44:586-691.Google Scholar
9.
Peters RK, Kjos SL, Xiang A, Buchanan TA. Long-term diabetogenic effect of single pregnancy in women with previous gestational diabetes mellitus.  Lancet.1996;347:227-230.Google Scholar
10.
Towner D, Kjos S, Leung B.  et al.  Congenital malformations in pregnancies complicated by NIDDM.  Diabetes Care.1995;18:1446-1451.Google Scholar
11.
Skouby SO, Kuhl C, Molsted-Pedersen L, Petersen K, Christensen MS. Triphasic oral contraception: metabolic effects in normal women and those with previous gestational diabetes.  Am J Obstet Gynecol.1985;153:495-500.Google Scholar
12.
Skouby SO, Anderson O, Saurbrey N.  et al.  Oral contraception and insulin sensitivity: in vivo assessment in normal women and women with previous gestational diabetes.  J Clin Endocrinol Metab.1987;64:519-523.Google Scholar
13.
Kjos SL, Shoupe D, Douyan S.  et al.  Effect of low-dose oral contraceptives on carbohydrate and lipid metabolism in women with recent gestational diabetes: results of a controlled, randomized, prospective study.  Am J Obstet Gynecol.1990;163:1822-1827.Google Scholar
14.
Kung AW, Ma JT, Wong VC.  et al.  Glucose and lipid metabolism with triphasic oral contraceptives in women with history of gestational diabetes.  Contraception.1987;35:257-269.Google Scholar
15.
National Diabetes Data Group.  Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.  Diabetes.1979;29:1039-1057.Google Scholar
16.
Cox DR. Regression models and life tables (with discussion).  J R Stat Soc B.1972;34:187-200.Google Scholar
17.
Delvoye P, Demaegd M, Uwayita-Nyampetea Robyn C. Serum prolactin, gonadotropins, and estradiol in menstruating and amenorrheic mothers during two years' lactation.  Am J Obstet Gynecol.1978;130:635-639.Google Scholar
18.
Howie PW, McNeilly AS, Houston MJ, Cook A, Boyle H. Fertility after childbirth: post-partum ovulation and menstruation in bottle and breast feeding mothers.  Clin Endocrinol (Oxf).1982;17:323-332.Google Scholar
19.
Battin DA, Marrs RP, Fleiss PM, Mishell DR. Effect of sucking on serum prolactin, luteinizing hormone, follicle-stimulating hormone, and estradiol during prolonged lactation.  Obstet Gynecol.1985;65:785-788.Google Scholar
20.
Kalkhoff RK. Metabolic effects of progesterone.  Am J Obstet Gynecol.1982;142:735-737.Google Scholar
21.
Godsland IF, Crook D, Simpson R.  et al.  The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.  N Engl J Med.1990;323:1375-1381.Google Scholar
22.
Perlman JA, Russell-Briefel R, Ezzati T.  et al.  Oral glucose tolerance and the potency of contraceptive progestins.  J Chronic Dis.1985;38:857-864.Google Scholar
23.
Spellacy WN, Buhi WC, Birk SA. The effect of estrogens on carbohydrate metabolism: glucose insulin and growth hormone studies one hundred seventy-one women ingesting Premarin, mestranol and ethinyl estradiol for six months.  Am J Obstet Gynecol.1972;114:378-392.Google Scholar
24.
Ryan EA, Enns L. Role of gestational hormones in the induction of insulin resistance.  J Clin Endocrinol Metab.1988;67:341-347.Google Scholar
25.
Wilcox JG, Hwang J, Hodis HN, Sevanian A, Stanczyk FZ, Lobo RA. Cardioprotective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and oxidation of low-density lipoprotein.  Fertil Steril.1997;67:57-62.Google Scholar
26.
Houssay BA, Foglia VG, Rodriguez RR. Production and prevention of some types of experimental diabetes by oestrogens and corticosteroids.  Acta Endocrinol.1954;17:146-164.Google Scholar
27.
Kjos SL, Henry O, Lee RM, Buchanan TA, Mishell Jr DR. The effect of lactation on glucose and lipid metabolism in women with recent gestational diabetes.  Obstet Gynecol.1993;82:451-455.Google Scholar
28.
Eizirik DL, Korbutt GS, Hellerstrom C. Prolonged exposure of human pancreatic islets to high glucose concentrations in vitro impairs Beta-cell function.  J Clin Invest.1992;90:1263-1268.Google Scholar
29.
Leahy JL, Bonner-Weir S, Weir GC. Beta-cell dysfunction induced by chronic hyperglycemia.  Diabetes Care.1992;15:442-455.Google Scholar
30.
Molsted-Pedersen L, Skouby SO, Damm P. Preconception counseling and contraception after gestational diabetes.  Diabetes.1991;40(suppl 2):147-150.Google Scholar
31.
Radberg T, Gustafson A, Skryten A, Karlsson K. Metabolic studies in gestational diabetic women during contraceptive treatment: effects on glucose tolerance and fatty acid composition of serum lipids.  Gynecol Obstet Invest.1982;13:17-29.Google Scholar
32.
Skouby SO, Molsted-Pedersen L, Kuhl C. Low dosage oral contraception in women with previous gestational diabetes.  Obstet Gynecol.1982;59:325-328.Google Scholar
33.
Pettitt DJ, Narayan KM, Hanson RL, Knowler WC. Incidence of diabetes mellitus in women following impaired glucose tolerance in pregnancy is lower than following impaired glucose tolerance in the non-pregnant state.  Diabetologia.1996;39:1334-1337.Google Scholar
34.
Schaefer UM, Songster G, Xiang A, Berkowitz K, Buchanan TA, Kjos SL. Congenital malformations in offspring of women with hyperglycemia first detected during pregnancy.  Am J Obstet Gynecol.1997;177:1165-1171.Google Scholar
35.
Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican Americans.  Diabetes.1995;44:1386-1391.Google Scholar
36.
DeFronzo RA. The triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM at Lilly: lecture 1987.  Diabetes.1988;37:667-687.Google Scholar
37.
Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn RC. Role of glucose and insulin resistance in the development of type 2 diabetes mellitus: results of a 25-year follow-up study.  Lancet.1992;340:925-929.Google Scholar
38.
Lillioja S, Mott DM, Spraul M.  et al.  Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus.  N Engl J Med.1993;329:1988-1992.Google Scholar
Original Contribution
August 12, 1998

Contraception and the Risk of Type 2 Diabetes Mellitus in Latina Women With Prior Gestational Diabetes Mellitus

Author Affiliations

From the Departments of Obstetrics and Gynecology (Drs Kjos, Schaefer, and Buchanan), Preventive Medicine (Drs Peters, Xiang, and Thomas), and Medicine (Dr Buchanan), University of Southern California School of Medicine, Los Angeles.

JAMA. 1998;280(6):533-538. doi:10.1001/jama.280.6.533
Abstract

Context.— Effective contraception is essential in women with prior gestational diabetes mellitus (GDM) but should not increase their already substantial risk of developing type 2 diabetes.

Objective.— To determine whether exposure to low-dose oral contraceptives increases the risk of developing type 2 diabetes mellitus in women with recent GDM.

Design.— Retrospective cohort study of 904 Latinas with GDM who gave birth between January 1987 and March 1994, in whom postpartum diabetes was excluded at 4 to 16 weeks post partum.

Interventions.— At their initial postpartum visit, 443 women selected a nonhormonal form of contraception, 383 received a low-dose, estrogen-progestin combination oral contraceptive (OC), and 78 breast-feeding women received the progestin-only OC. When breast-feeding ended, patients initially taking progestin-only OCs were switched to combination OCs. Patients were followed up periodically with oral glucose tolerance tests for up to 712 years.

Main Outcome Measures.— Person time was used to compute unadjusted average annual incidence rates of developing diabetes mellitus, as defined by the National Diabetes Data Group Criteria. Survival analysis was used to compute the unadjusted cumulative incidence rates and adjusted relative risks of diabetes mellitus.

Results.— The unadjusted average annual incidence rates of type 2 diabetes mellitus were 8.7%, 10.4%, and 26.5%, respectively, for patients using nonhormonal forms of contraception, combination OCs, and progestin-only OCs. Cumulative incidence rates were virtually identical for patients with uninterrupted use of combination OCs and nonhormonal forms of contraception, but patients using progestin-only OCs developed diabetes mellitus more rapidly during the first 2 years of use. After adjustment for potential confounding factors, the use of progestin-only OCs almost tripled the risk of type 2 diabetes mellitus compared with equivalent use of low-dose combination OCs (adjusted relative risk, 2.87; 95% confidence interval, 1.57-5.27). The magnitude of this risk increased with duration of uninterrupted use.

Conclusion.— Progestin-only OCs were associated with an increased risk of diabetes in breast-feeding Latinas with recent GDM and probably should be prescribed with caution, if at all, in these women. Long-term use of low-dose combination OCs did not increase the risk of type 2 diabetes compared with use of nonhormonal contraception. Thus, combination OCs do not appear to increase the risk of diabetes in non–breast-feeding women with recent GDM.

×